Stay updated on ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe page revision version was updated from v3.5.2 to v3.5.3 without changing the underlying study information presented.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check37 days agoChange DetectedAdded Hepatocellular carcinoma as a study condition and a Genetic and Rare Diseases Information Center resource link. The page revision updated from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check45 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check52 days agoChange DetectedMinor UI/layout adjustments and an updated timestamp; no substantive changes to core study content such as eligibility, primary outcomes, or treatment details.SummaryDifference0.1%

- Check74 days agoChange DetectedA new Revision: v3.4.2 is now visible. The funding lapse notice and the older Revision: v3.4.1 have been removed.SummaryDifference0.5%

Stay in the know with updates to ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page.